60 results on '"Nashan, B"'
Search Results
2. Proper patient selection leading to comparable major complication rate after ALPPS or non-ALPPS - a cohort study in a single institute
3. Proper patient selection leading to comparable major complication rate after ALPPS or non-ALPPS - a cohort study in a single institute
4. Is laparoscopic resection for lesions in the posterior segment better than open surgery?
5. Analysis of Risk Factors for Allograft Outcome Comparing 2 Kidneys From the Same Donor in Separate Recipients
6. Risk factors of bile leak and its consequence – single center study of 501 consecutive liver resections
7. FABIB: A proposed new severity grading system for liver surgery-specific complications
8. Impaired kinetic growth rate and increased posthepatectomy liver failure rates after ALPPS for colorectal liver metastasis
9. EpCAM-positive circulating tumor cells as liquid biomarker for early micrometastases and HCC recurrence risk
10. ALPPS technique evolution and oncological benefit – single center experience with 24 cases
11. Learning curve effect in ALPPS – A retrospect analysis of four years' experience
12. Prospective validation of the ‘FABIB’ liver surgery-specific complication severity grading system in 224 patients
13. Regarding “Compared Efficacy of Preservation Solutions in Liver Transplantation: A Long-Term Graft Outcome Study From the European Liver Transplant Registry”
14. Definition of Chronic Hepatitis E After Liver Transplant Conforms to Convention
15. P0748 : Course of HCV RNA and HCV core antigen testing are predictors for reaching SVR in transplant recipients
16. P1320 : Early everolimus-based tacrolimus reduction in de novo liver transplant recipients: Design and baseline data from Hephaistos study
17. P1310 : Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1) – a randomized, multidisciplinary, multinational phase III trial
18. Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study
19. P886 RELEVANCE OF CHRONIC HEPATITIS E IN LIVER TRANSPLANT RECIPIENTS: A REAL-LIFE-SETTING
20. P875 FIRST CASE REPORT OF A PATIENT WITH FIBROSING CHOLESTATIC HEPATITIS C AFTER LIVER TRANSPLANTATION TREATED WITH SOFOSBUVIR AND SIMEPREVIR
21. Cognitive Performance in Pediatric Liver Transplant Recipients
22. Sotrastaurin, a Novel Small Molecule Inhibiting Protein-Kinase C: Randomized Phase II Study in Renal Transplant Recipients
23. 406 Antibody Produced in the Presence of CNI Immunosuppression Contributes to Allograft Vasculopathy
24. 59 Dual targeting of mTOR and HSP90 for therapy of pancreato-biliary carcinomas
25. 556 Therapeutic siRNA delivery against PKN3 improves the antineoplastic efficacy of gemcitabine in an orthotopic pancreatic cancer model
26. 142: The Role of Alloantibody in the Development of Cardiac Allograft Vasculopathy
27. Proliferation Signal Inhibitors in Transplantation: Questions at the Cutting Edge of Everolimus Therapy
28. Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study
29. Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Stable Maintenance Renal Transplant Patients: Pooled Results From Three International, Multicenter Studies
30. FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia
31. Conversion to Enteric-Coated Mycophenolate Sodium From Various Doses of Mycophenolate Mofetil: Results of a Prospective International Multicenter Trial in Maintenance Renal Transplant Patients Receiving Cyclosporine
32. MDR1 C3435T Polymorphisms Correlate With Cyclosporine Levels in De Novo Renal Recipients
33. Update on liver transplantation using cyclosporine
34. PUK8 2-HOUR POST DOSE (C2) MONITORING VERSUS TROUGH (C0) MONITORING OF NEORAL: AN ECONOMIC EVALUATION
35. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the Myfortic Prospective Multicenter Study
36. 12 Active immunization after liver transplantation for HBV related liver disease: Failure to induce HBV-specific humoral and cellular immune responses
37. HBSAG level at time of olt determines hepatitis B immunoglobulin dose required for elimination of HBSAG after olt in patients with HBV cirrhosis
38. Basiliximab reduces acute liver allograft rejection in pediatric patients
39. Liver transplantation for liver cirrhosis in cystic fibrosis
40. Successful hepatitis B reinfection prophylaxis with lamivudine and hepatitis B immune globulin in patients with positive HBV-DNA at time of liver transplantation
41. Liver transplantation today
42. The IL2 pathway in clinical immunosuppression
43. The role of certican (everolimus, rad) in the many pathways of chronic rejection
44. Fast quantification method for sirolimus and its major metabolites
45. Prognostic relevance of proliferation and cell adhesion markers inliver transplantation for metastatic neuroendocrine tumors
46. The interleukin-2 inhibitors and their role in low-toxicity regimens
47. Treatment of chronic renal allograft failure by addition of mycophenolate mofetil: single-center experience in 40 patients
48. Can antibody prophylaxis allow sparing of other immunosuppressives?
49. Daclizumab: outcome of phase III trials and mechanism of action
50. Orthotopic domino liver transplantation in familial amyloidotic polyneuropathy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.